Great article kbear, thanks for posting. Even if it's anecdotal, it's nice to hear positive stories.
One thing that confuses me slightly in the discussion around the Four Corners story is everyone's description of survival benefits as an "average".
I'm almost certain Yervoy's approval was based on "median" data. And, unless all the patients have died, I'm not sure how they've arrived at an average figure.
"Average" undersells the benefit of immunotherapy which typically has a long survival tail. Just like CVac's trials will be measured, using medians, all it tells us is that the patient population (as tested) has a 50% chance of living longer than the median amount. It could be 1 day or it could be 50 years.
The survival curve isn't symmetrical, the distribution of events are concentrated quite closely in the first half of patients but extend out quite far in the second.
Every time I hear 'average survival' bandied about it makes me wince at the thought of people misunderstanding the actual data.
- Forums
- ASX - By Stock
- IMM
- worth watching..
worth watching.., page-15
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 33.5¢ | $2.184M | 6.253M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 107414 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 156342 | 0.345 |
8 | 173610 | 0.340 |
5 | 216592 | 0.335 |
11 | 170484 | 0.330 |
5 | 23066 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 107414 | 4 |
0.355 | 87437 | 2 |
0.360 | 96232 | 4 |
0.365 | 117195 | 6 |
0.370 | 119996 | 5 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |